Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu

Research Group Tumor Immunology and Immunotherapy of GI-Tumors

In recent years, immunotherapies are emerging as new treatment strategies for many types of cancer, but the response rates in many solid tumors are still very low. The efficacy of immunotherapy highly depends on an inflamed tumor phenotype with high infiltration of tumor-reactive T cells. Therefore, we are investigating the immune phenotype of GI-tumors as well as therapeutic strategies that have the potential to induce tumor-reactive T cells and improve efficacy of immunotherapies (eg. tumor vaccines). The results of these studies will be used to develop novel (combination) therapies.

You are here:

Research focus

  • Immunotherapy of gastrointestinal tumors
  • In situ vaccination for the treatment of hepatocellular carcinoma
  • Characterizing the immune landscape of gastrointestinal tumors
  • Circulating biomarkers in patients with hepatocellular carcinoma
  • Circulating biomarkers in patients with neuroendocrine tumors
  • Refinement methods (3R) to improve animal welfare in mouse models of liver cancer

Principal Investigator

Team Members


Johanna Kusnick, MSc

Robin Schmidt, cand med

top left to bottom right: Johanna Kusnick, Kirsten Reers, Anne Schlutt, Jana Knorr-Klocke, Wiebke Werner, Alix Bruneau, Isabella Lurje, Linda Hammerich © Linda Hammerich


Hepatic inflammatory responses in liver fibrosis
Hammerich L, Tacke F.
Nat Rev Gastroenterol Hepatol. 2023 Oct;20(10):633-646.

Resolving 31 colors on a standard 3-laser full spectrum flow cytometer for immune monitoring of human blood samples
Hammerich L, Shevchenko Y, Knorr J, Werner W, Bruneau A, Tacke F.
Cytometry B Clin Cytom. 2023 May 20

Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms
Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, Tacke F, Wiedenmann B, Roderburg C, Hammerich L.
Endocr Relat Cancer. 2023 Jun 2;30(7):e220357.

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
Wiering L, Subramanian P, Hammerich L.
Cell Mol Gastroenterol Hepatol. 2023;15(6):1277-1292.

Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer.
Roderburg C, Labuhn S, Bednarsch J, Lang SA, Schneider AT, Hammerich L, Vucur M, Ulmer TF, Neumann UP, Luedde T, Loosen SH.
Mediators Inflamm. 2022 Dec 1;2022:6195004.

Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.
Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, [...],Brody JD.
Nat Commun. 2022 Nov 22;13(1):7149.

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors.
Geisler L, Hellberg T, Lambrecht J, Jann H, Knorr J, Eschrich J, Loosen SH, Wree A, Hammerich L, Krieg A, Luedde T, Tacke F, Roderburg C, Mohr R.
J Clin Med. 2022 Oct 20;11(20):6191

Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
Engelmann C, Habtesion A, Hassan M, Kerbert AJ, Hammerich L, [...], Jalan R. 
J Hepatol. 2022 Nov;77(5):1325-1338

Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells
Krause N, [...], Hammerich L, Tacke F, Haas JF, Müller T, Utku N
Front Immunol. 2022 Feb 8;12:790775

Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma
Kusnick J, Bruneau A, Tacke F, Hammerich L*
Immuno 2022, 2(1), 185-217;

Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
Detjen KM, Otto R, [...] Tacke F, Roderburg C*, Hammerich L*.
Cancers (Basel). 2021 Sep 4;13(17):4463. doi: 10.3390/cancers13174463.

The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors.
Geisler L, Mohr R, [...] Hammerich L, Tacke F, Wree A, Hellberg T, Roderburg C.
Int J Mol Sci. 2021 Aug 9;22(16):8569. doi: 10.3390/ijms22168569

In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma.
Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L.
Front. Immunol. 22 Apr 2021. doi: 10.3389/fimmu.2021.650486

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, [...] Roderburg C.
Front Immunol. 2021 Mar 30;12:652172.

Serum levels of circulatin microRNA-107 are elevated in patients with early-stage HCC.
Loosen SH, Castoldi M, Jördens MS, Roy S, Vucur M, Kandler J, Hammerich L, [...] Roderburg C.
PLoS One. 2021 Mar 12;16(3):e0247917. doi: 10.1371/journal.pone.0247917.

From liver cirrhosis to cancer: The role of Micro-RNAs in Hepatocarcinogenesis.
Mohr R, Özdirik B, Lambrecht J, Demir M, [...] Tacke F, Hammerich L*, Roderburg C*.
Int J Mol Sci. 2021 Feb 2;22(3):1492. doi: 10.3390/ijms22031492.

Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer.
Lurje I, Hammerich L, Tacke F.
Int. J. Mol. Sci. 2020, 21(19), 7378. doi: 10.3390/ijms21197378.

Models of gastroenteropancreatic neuroendocrine neoplasms - Current status and future directions.
Detjen K*, Hammerich L*, Özdirik B, Demir M, Wiedenmann B, Tacke F, Jann H, Roderburg C.
Neuroendocrinology. 2021;111(3):217-236.